

Special Issue

Recent Developments of Coagulation Factor Products in Hemophilia Treatment

Message from the Guest Editor

In recent years, hemophilia therapy has made significant progress. Several new drugs have been added to the list of available treatments, significantly improving patients' quality of life. The extended half-life factor concentrates have enabled a reduced number of infusions, maintaining (and indeed, often increasing) the efficacy of treatments. These new drugs have also led to a reduction in bleeding, bringing us one step closer to the coveted "zero bleeds", which is the ultimate goal of clinicians and patients. Another advantage of these concentrates is their versatility; thanks to the use of pharmacokinetics and an accurate anamnesis that considers the needs and wishes of the patients, optimal personalized therapy can now be defined. This Special Issue aims to highlight every aspect of these new coagulation factor concentrates, their efficacy, their safety, and their impact on patients' lives. Original articles, brief reports, communications, research articles, and reviews are welcome.

Guest Editor

Dr. Samantha Pasca

Department of Biomedical Sciences (DSB), University Hospital of Padua, 35138 Padua, Italy

Deadline for manuscript submissions

closed (20 August 2023)



Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/160162

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us. We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)